CGM-guided dietary titration improves Time in Range in GSD patients
In interventional settings, CGM-guided dietary titration improved Time in Range from 72% to 86% in gene therapy trials, and reduced serum triglycerides and liver size. CGM consistently identified asymptomatic hypoglycemia, with adult cohorts spending up to 12% of time below range despite normal spot checks.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
CGM-guided dietary titration improves Time in Range in GSD patients The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 38/100 (low).
The Claim
CGM-guided dietary titration improves Time in Range in GSD patients
This conclusion is most relevant to: Patients with hepatic Glycogen Storage Diseases (GSD), predominantly subtypes Ia, Ib and III (N=323 across 31 studies).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Continuous Glucose Monitoring in Glycogen Storage Diseases: A Systematic Review of Clinical Utility, Accuracy and Patient Outcomes. (Endocrinology, diabetes & metabolism, 2026) —
How It Works
The proposed biological pathway:
- ▸CGM provides continuous glucose data
- ▸Data enables precise dietary adjustments
- ▸Dietary titration stabilizes glucose levels
- ▸Result: improved Time in Range and reduced metabolic markers
Who Might Benefit
Evidence fit by population:
- ▸Patients with hepatic Glycogen Storage Diseases (GSD), predominantly subtypes Ia, Ib and III (N=323 across 31 studies)
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Sensor performance showed a positive bias in the hypoglycemic range, potentially masking severe neuroglycopenia
- ▸CGM introduced 'alarm fatigue' from false-positive alerts
Frequently Asked Questions
What is the main benefit of CGM in GSD?▼
CGM offers superior sensitivity for detecting occult (asymptomatic) hypoglycemia and guiding dietary therapy, potentially shifting management from reactive treatment to proactive stabilization.
What are the downsides of CGM in GSD patients?▼
Sensor inaccuracy at lower glucose levels (positive bias) may mask severe neuroglycopenia, and constant surveillance can lead to alarm fatigue from false-positive alerts.
How much time do GSD adults spend below glucose range despite normal spot checks?▼
Adult cohorts spent up to 12% of time below range (< 70 mg/dL) despite normal spot checks.
What improvements were seen with CGM-guided dietary titration in gene therapy trials?▼
Time in Range improved from 72% to 86%, and reductions in serum triglycerides and liver size were observed.
References
- 1.Mohsenipour R, Abbasi F, Ghaderian MS, Dehkordi AK, Abdolahpour S, Akbari K. “Continuous Glucose Monitoring in Glycogen Storage Diseases: A Systematic Review of Clinical Utility, Accuracy and Patient Outcomes..” Endocrinology, diabetes & metabolism, 2026. PMID: 42394382 DOI: 10.1002/edm2.70274